India's Alembic Pharma posts quarterly profit rise on strong generics demand

Alembic Pharmaceuticals

04/08/2026 10:21

Aug 4 (Reuters) - India's Alembic Pharmaceuticals ALEM.NS on Tuesday reported a 12.1% increase in first-quarter profit, driven by strong demand for generic drugs in its key U.S. market.
Consolidated profit after non-controlling interests rose to 1.73 billion rupees ($18.14 million), from 1.54 billion rupees last year.
Alembic Pharmaceuticals, as well as several Indian peers that make generic drugs, derive a large part of their revenues from the U.S.
The company's revenue from its U.S. generics business jumped nearly 49% to 7.78 billion rupees.
Seven products were launched in the quarter in the U.S., the company said.
The company added that more than 15 product are expected to be launched in the U.S. in fiscal 2027.
Alembic Pharma's active pharmaceutical ingredient (API) revenue grew by 32.6%.
Revenue from the company's non-U.S. international revenue expanded by about 17%.
Expenses grew by 27.3%, mainly driven by an increase in other expenses and cost of materials consumed.
The company's consolidated revenue from operations grew 25.7% to 21.5 billion rupees.
Shares of the company rose as much as 2.4% after the results, paring gains later to trade 0.3% higher.
($1 = 95.3800 Indian rupees)

 (Reporting by Abhirami G in Bengaluru; Editing by Nivedita Bhattacharjee)
 ((abhirami.g@thomsonreuters.com))